Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Botulinum Toxin Type A for Crow's Feet and Frown Lines
NCT01224015Phase 3Completed
- Sponsor
- Allergan
- Start
- May 2011
- Primary completion
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of onabotulinumtoxinA in facial rhytides (3 arms), sponsored by Allergan. Primary endpoint: Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Day 30. Started May 2011; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
facial rhytides
Beyond the preview
Go deeper on NCT01224015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01224015.